Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Nasdaq

ThermoGenesis Holdings's Earnings: A Preview

ThermoGenesis Holdings (NASDAQ:THMO) is set to give its latest quarterly earnings report on Monday, 2022-03-28. Here's what investors need to know before the announcement. Analysts estimate that ThermoGenesis Holdings will report an earnings per share (EPS) of $-0.06.

Benzinga

Eyenovia's Earnings Outlook

Eyenovia (NASDAQ:EYEN) is set to give its latest quarterly earnings report on Monday, 2022-03-28. Here's what investors need to know before the announcement. Analysts estimate that Eyenovia will report an earnings per share (EPS) of $-0.22.

Benzinga

Earnings Preview For Reshape Lifesciences

Reshape Lifesciences (NASDAQ:RSLS) is set to give its latest quarterly earnings report on Monday, 2022-03-28. Here's what investors need to know before the announcement. Analysts estimate that Reshape Lifesciences will report an earnings per share (EPS) of $-0.17.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Trxade Group Earnings Preview

Trxade Group (NASDAQ:MEDS) is set to give its latest quarterly earnings report on Monday, 2022-03-28. Here's what investors need to know before the announcement. Analysts estimate that Trxade Group will report an earnings per share (EPS) of $-0.15.

Benzinga

Earnings Outlook For Hallador Energy

Hallador Energy (NASDAQ:HNRG) is set to give its latest quarterly earnings report on Monday, 2022-03-28. Here's what investors need to know before the announcement. Analysts estimate that Hallador Energy will report an earnings per share (EPS) of $-0.02.

Benzinga

Earnings Outlook For Venus Concept

Venus Concept (NASDAQ:VERO) is set to give its latest quarterly earnings report on Monday, 2022-03-28. Here's what investors need to know before the announcement. Analysts estimate that Venus Concept will report an earnings per share (EPS) of $-0.10.

Benzinga

Mid-Morning Market Update: Markets Mixed; US Pending Home Sales Index Drop 4.1%

U.S. stocks traded opened on a mixed note this morning, with the Dow Jones gaining around 80 points on Friday.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Analyzing Lam Research Corporation's Short Interest

Lam Research Corporation's (NASDAQ:LRCX) short percent of float has risen 9.77% since its last report. The company recently reported that it has 2.03 million shares sold short, which is 1.46% of all regular shares that are available for trading.

Benzinga

Analyst Ratings For Ollie's Bargain Outlet

Ollie's Bargain Outlet (NASDAQ:OLLI) has observed the following analyst ratings within the last quarter:

Benzinga

Dave & Buster's Enter's Earnings: A Preview

Dave & Buster's Enter (NASDAQ:PLAY) is set to give its latest quarterly earnings report on Monday, 2022-03-28. Here's what investors need to know before the announcement. Analysts estimate that Dave & Buster's Enter will report an earnings per share (EPS) of $0.61.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 25, 2022

Upgrades For Aris Water Solutions Inc (NYSE:ARIS), Capital One upgraded the previous rating of Equal-Weight to Overweight. The stock has a 52-week-high of $19.16 and a 52-week-low of $10.06. At the end of the last trading period, Aris Water Solutions closed at $18.55.

Benzinga

Preview: Brainstorm Cell's Earnings

Brainstorm Cell (NASDAQ:BCLI) is set to give its latest quarterly earnings report on Monday, 2022-03-28. Here's what investors need to know before the announcement. Analysts estimate that Brainstorm Cell will report an earnings per share (EPS) of $-0.20.

Benzinga

Looking Into Yumanity Therapeutics's Return On Capital Employed

Benzinga Pro data, Yumanity Therapeutics (NASDAQ:YMTX) reported Q4 sales of $762.00 thousand. Earnings fell to a loss of $10.41 million, resulting in a 4.57% decrease from last quarter.

Benzinga

ADMA Biologics's Return On Capital Employed Overview

According to data from Benzinga Pro, during Q4, ADMA Biologics's (NASDAQ:ADMA) reported sales totaled $26.38 million. Despite a 6.0% increase in earnings, the company posted a loss of $16.65 million.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Looking Into PhaseBio Pharmaceuticals's Return On Capital Employed

Benzinga Pro data, PhaseBio Pharmaceuticals (NASDAQ:PHAS) reported Q4 sales of $158.00 thousand. Earnings fell to a loss of $43.11 million, resulting in a 35.04% decrease from last quarter.

Benzinga

Looking Into TFF Pharmaceuticals's Return On Capital Employed

Benzinga Pro data, TFF Pharmaceuticals (NASDAQ:TFFP) reported Q4 sales of $12.00 thousand. Earnings fell to a loss of $10.05 million, resulting in a 15.8% decrease from last quarter.

Benzinga

Recap: DXP Enterprises Q4 Earnings

DXP Enterprises (NASDAQ:DXPE) reported its Q4 earnings results on Friday, March 25, 2022 at 09:20 AM. Here's what investors need to know about the announcement.

Benzinga

Looking Into Sigma Labs's Return On Capital Employed

According to Benzinga Pro data, during Q4, Sigma Labs (NASDAQ:SGLB) posted sales of $349.24 thousand. Earnings were up 3.76%, but Sigma Labs still reported an overall loss of $2.40 million.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Sight Sciences's Return On Capital Employed Overview

According to data from Benzinga Pro, during Q4, Sight Sciences's (NASDAQ:SGHT) reported sales totaled $14.69 million. Despite a 7.18% increase in earnings, the company posted a loss of $15.94 million.

Benzinga

One Stop Systems's Return On Capital Employed Insights

One Stop Systems (NASDAQ:OSS) brought in sales totaling $17.78 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 139.38%, resulting in a loss of $386.24 thousand.

Benzinga

Aptevo Therapeutics Earnings Perspective: Return On Capital Employed

According to Benzinga Pro data, during Q4, Aptevo Therapeutics (NASDAQ:APVO) posted sales of $3.67 million. Earnings were up 10.36%, but Aptevo Therapeutics still reported an overall loss of $6.27 million.

Benzinga

HOOKIPA Pharma's Return On Capital Employed Overview

Benzinga Pro data, HOOKIPA Pharma (NASDAQ:HOOK) reported Q4 sales of $3.90 million. Earnings fell to a loss of $21.23 million, resulting in a 5.96% decrease from last quarter.

Benzinga

AutoWeb Earnings Perspective: Return On Capital Employed

According to Benzinga Pro data, during Q4, AutoWeb (NASDAQ:AUTO) posted sales of $17.80 million. Earnings were up 14.63%, but AutoWeb still reported an overall loss of $2.61 million.

Benzinga

Co-Diagnostics's Return On Capital Employed Insights

Pulled from Benzinga Pro data, Co-Diagnostics (NASDAQ:CODX) posted Q4 earnings of $7.50 million, an increase from Q3 of 34.66%. Sales dropped to $20.40 million, a 32.22% decrease between quarters.

Benzinga

Why Cyren Stock Is Trading Lower Today

CYREN Ltd (NASDAQ: CYRN) is trading lower Friday after the company reported worse-than-expected revenue results. Cyren said fourth-quarter revenue declined from $8.4 million to $7.4 million year-over-year, which came in below the $7.77 million estimate.

1 … 825 826 827 828

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Places

United States

395,382 stories

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.